Novel evidence synthesis system to support living systematic reviews and living guidelines for cancer immunotherapy.
Lists
Only you see this
Abstract
2054 Background: Systematic reviews that summarize the toxicity of Immune checkpoint inhibitors (ICIs) become outdated very soon after publication. Therefore, we reported results of a toxicity meta-analysis at 2019 ASCO meeting and informed the intent to create a living systematic review (LSR). LSRs combine human and machine effort and support rapid evidence synthesis and living clinical practice guidelines. Now, we report our experience maintaining a LSR on toxicity of ICIs. Methods: Steps include quarterly literature searches to identify new clinical trials reporting ICI-associated adverse events (AEs), AI-enabled screening of new citations which meet the inclusion criteria, automated cumulative meta-analysis and an online reporting platform. Standard data formats and protocols were designed for inputting text, tables and graphics. Software was written to interpret these data and output the information in the appropriate format, such as a forest plot and summary tables. Finally, a dynamic interface that enables user inputs and displays the associated output was designed. Results: The LSR is continuously updated incorporating toxicity data from new clinical trials as it becomes available. We have screened 8000 relevant citations and summarized the odds of Grade 3 or higher AEs and AEs of special interest in patient receiving ICIs. The results are updated on quarterly basis and are available online. The results are updated on quarterly basis and will be available on a website at the time of publication. Prototype with dummy data is available at this link . This interface can also be manipulated via user input to organize and sort data tables and forest plots by type of cancer, name or mechanism (PD-1 or PD-L1) of ICI agent, single agent or combination, type of control arm, line of treatment and several other clinically relevant filters. For example, a user can instantaneously generate a meta-analysis summarizing the risk of colitis or pneumonitis in metastatic lung cancer trials with pembrolizmuab. Conclusions: This LSR engine can prospectively synthesize toxicity data from ICI trials in an efficient manner providing accurate and timely information for advanced clinical decision support at point-of-care. Efforts are ongoing to improve efficiency of screening, improve AI-enabled processes for automated screening and data abstraction, and test across multiple clinical questions.
BibTeX
@article{riaz2020novel,
author = {Irbaz Bin Riaz and Samarth Rawal and Rabbia Siddiqi and Noureen Asghar and Mahnoor Islam and Ognjen Gajic and Zhen Wang and Víctor M. Montori and Vitaly Herasevich and Ronald S. Go and Chitta Baral and Hongfang Liu and Per Olav Vandvik and Tufia C. Haddad and Alan H. Bryce and S. Vincent Rajkumar and M. Hassan Murad},
title = {{Novel evidence synthesis system to support living systematic reviews and living guidelines for cancer immunotherapy.}},
journal = {Journal of Clinical Oncology},
year = {2020},
doi = {10.1200/jco.2020.38.15\_suppl.2054},
}Loading related content...